DNLI DENALI THERAPEUTICS INC
2026Q1 · CUSIP 24823R105 · Sector: Healthcare & Biotech
Neutral · No signal
Holders
266
Δ holders QoQ
+15
Breadth percentile
Top 21%
Whale holders
133
Δ whales
+6
Inst. holding value
$2.8B
New positions
53
Closed positions
38
Price momentum (1Q)
-4.6%
Put / Call
6/8
Breadth history (34 quarters)
Past Lit Events & Aftermath 8 lit events
| Period | Percentile | Next-1Q return | Next-2Q return |
|---|---|---|---|
| 2022Q3 | Top 10% | -0.4% | +3.1% |
| 2020Q4 | Top 17% | -15.4% | -18.3% |
| 2020Q3 | Top 11% | -0.8% | -13.1% |
| 2020Q2 | Top 18% | +109.1% | +101.5% |
| 2020Q1 | Top 3% | +31.8% | +175.6% |
| 2019Q1 | Top 12% | -12.4% | -27.6% |
| 2018Q3 | Top 18% | +8.2% | +8.0% |
| 2018Q1 | Top 17% | -14.8% | -7.9% |
Options Sentiment
Put holders
6
QoQ: +5
Call holders
8
QoQ: +4
See methodology →
Fundamentals
PE (TTM)
—
EPS (TTM)
$-2.88
EPS YoY
—
Revenue (TTM)
—
Revenue YoY
—
Net margin
—
ROE
-54.9%
Debt ratio
26.9%
FCF (TTM)
-$419M
Dividend (TTM)
No dividend
Quarterly Revenue & EPS (4Y)
Quarterly figures; EPS split-adjusted, early quarters hidden when not calibrable
As of 2026-03-31 · SEC filings (XBRL)
Get the next update
2026Q2 holdings publish around Aug 15 — subscribe to receive the lists first.